Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Henley

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Alzheimer'S Research & Therapy|May 16, 2020
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension studyGerald Novak, Johannes Rolf Streffer, Maarten Timmers, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Understanding recent advances in non-amyloid/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer's diseaseLinda J Van Eldik, Eric R Siemers, Emily C Collins, et al.
Alzheimer'S Research & Therapy|December 7, 2023
The age-specific comorbidity burden of mild cognitive impairment: a US claims database studyGang Li, Nicola Toschi, Viswanath Devanarayan, et al.
Neurology. Clinical Practice|April 8, 2024
Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized TrialJoshua D Grill, Rema Raman, Karin Ernstrom, et al.
JAMA Neurology|January 19, 2021
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical TrialReisa Sperling, David Henley, Paul S Aisen, et al.
The Journal of Clinical Endocrinology and Metabolism|December 1, 2005
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromesDiana E Benn, Anne-Paule Gimenez-Roqueplo, Jennifer R Reilly, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 23, 2025
Tau biology, biomarkers, and therapeuticsBess Frost, Hartmuth Kolb, Alicia Algeciras-Schimnich, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Alzheimer'S Research & Therapy|May 16, 2020
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension studyGerald Novak, Johannes Rolf Streffer, Maarten Timmers, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Understanding recent advances in non-amyloid/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer's diseaseLinda J Van Eldik, Eric R Siemers, Emily C Collins, et al.
Alzheimer'S Research & Therapy|December 7, 2023
The age-specific comorbidity burden of mild cognitive impairment: a US claims database studyGang Li, Nicola Toschi, Viswanath Devanarayan, et al.
Neurology. Clinical Practice|April 8, 2024
Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized TrialJoshua D Grill, Rema Raman, Karin Ernstrom, et al.
JAMA Neurology|January 19, 2021
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical TrialReisa Sperling, David Henley, Paul S Aisen, et al.
The Journal of Clinical Endocrinology and Metabolism|December 1, 2005
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromesDiana E Benn, Anne-Paule Gimenez-Roqueplo, Jennifer R Reilly, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 23, 2025
Tau biology, biomarkers, and therapeuticsBess Frost, Hartmuth Kolb, Alicia Algeciras-Schimnich, et al.
Pageof 4